CD83 is a Targetable Inflammatory Marker of KRAS Mutant Cells in Myeloid Malignancies
KRAS mutations are enriched in resistant myeloid neoplasms and are associated with poor prognosis. The lack of distinct surface markers makes it difficult to distinguish RAS-mutant leukemic stem and progenitor cells from normal counterparts and define their functional properties within mixed human bone marrow populations. Thus, Genotyping of Transcriptomes was performed across a spectrum of myeloid malignancies and showed that KRAS mutant cells formed a distinct inflammatory, stem/progenitor-like population characterized by CD83 overexpression. CD83+ mutant cells displayed impaired differentiation, whereas CD83 blockade in a novel transplantable KrasG12D mouse model reduced leukemogenic potential and prolonged survival. Selective KRASG12D inhibition in patient samples and in vivo promoted erythroid differentiation, reduced monocytosis and tumor burden, and reversed inflammatory cytokine production. The transplantable KrasG12D model recapitulated human disease, including extramedullary granulocytic tumors, and responded to treatment with a selective KRASG12D inhibitor. These findings identify CD83 as a novel therapeutic target across KRASG12D-mutant myeloid neoplasms.
Authors
- Amittha Wickrema (ORCID: https://orcid.org/0000-0003-4035-3014)
- Divij Verma (ORCID: https://orcid.org/0000-0002-2214-9450)
- Rahul Sanawar (ORCID: https://orcid.org/0000-0002-1168-7747)
- Srinivas Aluri (ORCID: https://orcid.org/0000-0003-4084-1747)
- Marina Y Konopleva (ORCID: https://orcid.org/0000-0002-9347-2212)
- Milagros Carbajal
- Leah Kravets (ORCID: https://orcid.org/0000-0002-2242-0087)
- Lindsay M. LaFave (ORCID: https://orcid.org/0000-0002-5203-4961)
- Amit Verma (ORCID: https://orcid.org/0000-0002-5408-1673)
- Shanisha A. K. Gordon
- Mirca Saras Saurty-Seerunghen (ORCID: https://orcid.org/0000-0002-9541-4921)
- Hussein A. Abbas (ORCID: https://orcid.org/0000-0003-2946-3562)
- Ulrich G. Steidl (ORCID: https://orcid.org/0000-0002-9458-1795)
- Mendel Goldfinger (ORCID: https://orcid.org/0000-0002-4347-173X)
- Ariel A. Fromowitz
- Chi-Lam Poon (ORCID: https://orcid.org/0000-0001-6298-7099)
- Swathi-Rao Narayanagari (ORCID: https://orcid.org/0000-0003-3372-1501)
- Aditi Shastri (ORCID: https://orcid.org/0000-0003-3650-0800)
- Anna S. Nam (ORCID: https://orcid.org/0000-0003-4192-8916)
- Srabani Sahu (ORCID: https://orcid.org/0009-0002-3667-3592)
- Rongbao Zhao
- Olivia Sakaguchi
- Jinghang Zhang
- Jingli Wang
- Ritesh Agarwal
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- Weill Cornell Medicine (US)
- Montefiore Einstein Comprehensive Cancer Center (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11528826/v1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- preprint